文献速递核素与放射性配体治疗肿瘤 PET/CT

骨主导型mCRPC患者首周期177Lu-PSMA后突发弥漫性肝转移

Sudden Diffuse Hepatic Metastases After First 177Lu-PSMA Cycle in Bone Predominant mCRPC Patient.
PubMed 文献 · Clin Nucl Med · 2025-10-16

一例63岁转移性去势抵抗性前列腺癌(mCRPC)患者,伴广泛骨及多发淋巴结转移,接受177Lu-PSMA治疗。第二疗程后扫描显示全肝多发活性增高灶,符合弥漫性肝转移,而诊断性扫描及首次治疗后扫描与SPECT/CT均未见此表现。肝穿刺活检证实为前列腺腺癌转移。

要点

  • 177Lu-PSMA治疗后新发弥漫性肝转移可出现在骨主导型mCRPC患者中。
  • 诊断性及首周期治疗后扫描与SPECT/CT均未显示肝转移,第二疗程后扫描才发现。
  • 肝穿刺活检证实为前列腺腺癌转移,明确了诊断。

核心结论

  • 首周期177Lu-PSMA治疗后突发弥漫性肝转移为意外发现,肝穿刺活检证实为前列腺腺癌转移。

研究设计与样本

  • 个案报道:63岁mCRPC患者,伴广泛骨及多发淋巴结转移,接受177Lu-PSMA治疗。

主要发现

  • 第二疗程后扫描显示全肝多发活性增高灶,符合弥漫性肝转移,诊断性扫描及首次治疗后扫描与SPECT/CT均未见。
  • 该意外发现使医疗团队面临临床困境,最终肝穿刺活检证实为前列腺腺癌转移。

临床怎么用

  • 对177Lu-PSMA治疗后出现的新发肝部活性灶应警惕弥漫性肝转移,必要时行活检确认。

局限性

  • 个案报道,结论不能推广至全部mCRPC患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present a 63-year-old man with a history of prostate adenocarcinoma (mCRPC), widespread skeletal and multiple lymph node metastases, who was referred for 177Lu-PSMA therapy. In second course of therapy, posttreatment scan showed multiple foci of increased activity throughout the liver, compatible with diffuse hepatic metastases, which were not seen in the diagnostic and the first posttreatment scans and SPECT/CT images. This unexpected finding turned the case into a clinical dilemma, leaving the medical team uncertain about how best to proceed to ensure the most appropriate care. Eventually, a liver FNA confirmed the presence of metastatic prostatic adenocarcinoma.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Samadi MH, Forouzanian S, Sahafi P, et al. Sudden Diffuse Hepatic Metastases After First 177Lu-PSMA Cycle in Bone Predominant mCRPC Patient. Clin Nucl Med. 2025. PMID: 42247620. doi:10.1097/RLU.0000000000006170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。